 |
 |
 |
 |
 |
 |
 |
このサイトは医療関係者の方々を対象に作成しています。必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
 |
 |
 |
 |
 |
 |
Colorectal Cancer |  |
Non-Colorectal Cancer |
 |
|
|
|
A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). |
|
|
|
|
| German AIO (pIII)：進行膵癌におけるgemcitabine+erlotinib併用療法後のcapecitabine投与vs. capecitabine+erlotinib併用療法後のgemcitabine投与 | |
|
|
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer : A randomized, cross-over phase III trial of the AIO |
|
|
|
|
|
|
Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. |
|
|
|
|
局所限局食道癌に対する手術単独療法 (S群) と術前化学放射線療法+手術療法 (CRT群) の検討：無作為化第III相試験FFCD 9901 |
|
|
|
Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. |
|
|
|
|
転移性膵癌に対する1st-lineとしてのFOLFIRINOX vs gemcitabineの無作為化比較第III相試験：PRODIGE 4/ACCORD 11試験 (pIII) |
|
|
|
Randomized phase III trial comparing FOLFIRINOX (F:5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as 1st-line treatment for metastatic pancreatic adenocarcinoma (MPA) :PRODIGE 4/ACCORD 11 trial. |
|
|
